

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)



(10) International Publication Number
WO 2021/260197 A1

(51) International Patent Classification:

A61K 31/7088 (2006.01) A61P 31/14 (2006.01)

C12N 15/113 (2010.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2021/067550

(22) International Filing Date:

25 June 2021 (25.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20182437.2 26 June 2020 (26.06.2020) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road, 8th floor, Little Falls, New Jersey 07424 (US).

(72) Inventors: **SEWING, Sabine**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **OTTOSEN, Søren**; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Hørsholm (DK). **RAVN, Jacob**; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Hørsholm (DK). **PEDERSEN, Lykke**; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Hørsholm (DK). **LUANGSAY, Souphalane**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **KOLLER, Erich**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **WALTHER, Johanna Marie**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **GYLLING, Helene Maria**; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Hørsholm (DK). **HRUSCHKA, Natascha**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **MOHR, Susanne**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **D'ARIENZO, Valentina**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH).

(74) Agent: **ALTMANN STÖSSEL DICK PATENTANWÄLTE PARTG MBB**; Theodor-Heuss-Anlage 2, 68165 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION

(57) Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection, or its use in the treatment of cancer.



WO 2021/260197 A1